The mutation site and the targeted therapy of RET proto-oncogene in medullary thyroid carcinoma
10.3760/cma.j.issn.1674-6090.2018.05.017
- VernacularTitle:甲状腺髓样癌RET基因突变的位点分析与靶向治疗进展
- Author:
Wenjuan CAO
1
;
Daqi ZHANG
;
Hui SUN
Author Information
1. 130033长春,吉林大学中日联谊医院甲状腺外科,吉林省外科转化医学重点实验室,吉林省甲状腺疾病防治工程实验室
- Keywords:
Medullary thyroid carcinoma;
RET proto-oncogene;
MEN2;
Targeted therapy
- From:
Chinese Journal of Endocrine Surgery
2018;12(5):426-429
- CountryChina
- Language:Chinese
-
Abstract:
Medullary thyroid carcinoma (MTC) is an endocrine tumor originating from the parafollicular cells of the thyroid gland.The mutation of RET gene has been considered as the molecular basis of MTC.Different types of MTC have different RET mutation sites,and the corresponding clinical manifestations and prognosis are also very different.RET gene detection is helpful for individual accurate gene diagnosis,molecular risk assessment,individual analysis and early prevention management.Nowadays,targeted therapy for RET gene mutations in MTC has developed rapidly.Some of those drugs,which have been approved for clinical application,bring new hope for advanced MTC.
